Table 4.
Baseline characteristics of IFG and normal groups defined by different cut-off points before and after PSM in female patients.
| Cut-off point of IFG | Age | Hypertension | Smoking | Drinking | Dyslipidemia | Chronic kidney disease | Previous ischemic stroke | CHD | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 5 mmol/L | Before PSM | NG (n = 387) | 56 (50–65) | 262 (67.7%) | 3 (0.8%) | 3 (0.8%) | 128 (33.1%) | 3 (0.8%) | 37 (9.6%) | 177 (45.7%) |
| IFG (n = 639) | 61 (53–66) | 461 (72.1%) | 9 (1.4%) | 6 (0.9%) | 236 (36.9%) | 4 (0.6%) | 49 (7.7%) | 360 (56.3%) | ||
| p value | <0.001 | 0.130 | 0.551 | 1 | 0.211 | 1 | 0.289 | 0.001 | ||
| After PSM | NG (n = 376) | 57 (51–65) | 252 (67%) | 3 (0.8%) | 3 (0.8%) | 126 (33.5%) | 3 (0.8%) | 34 (9%) | 167 (44.4%) | |
| IFG (n = 376) | 57 (52–65) | 259 (68.9%) | 2 (0.5%) | 2 (0.5%) | 146 (38.8%) | 1 (0.3%) | 34 (9%) | 193 (51.3%) | ||
| p value | 0.755 | 0.584 | 1 | 1 | 0.129 | 0.624 | 1 | 0.058 | ||
| 5.1 mmol/L | Before PSM | NG (n = 462) | 57 (50∼65) | 309 (66.9%) | 3 (0.6%) | 3 (0.6%) | 152 (32.9%) | 3 (0.6%) | 41 (8.9%) | 214 (46.3%) |
| IFG (n = 564) | 61 (53–67) | 414 (73.4%) | 9 (1.6%) | 6 (1.1%) | 212 (37.6%) | 4 (0.7%) | 45 (8.0%) | 323 (57.3%) | ||
| p value | <0.001 | 0.023 | 0.161 | 0.525 | 0.118 | 1 | 0.606 | < 0.001 | ||
| After PSM | NG (n = 400) | 60 (52–65) | 289 (72.3%) | 1 (0.3%) | 2 (0.5%) | 133 (33.3%) | 3 (0.8%) | 41 (10.3%) | 179 (44.8%) | |
| IFG (n = 400) | 60 (53–65) | 264 (66.0%) | 5 (1.3%) | 5 (1.3%) | 141 (35.3%) | 3 (0.8%) | 29 (7.3%) | 203 (50.8%) | ||
| p value | 0.523 | 0.056 | 0.217 | 0.255 | 0.551 | 1 | 0.133 | 0.089 | ||
| 5.2 mmol/L | Before PSM | NG (n = 528) | 58 (51–65) | 357 (67.6%) | 6 (1.1%) | 4 (0.8%) | 181 (34.3%) | 3 (0.6%) | 42 (8.0%) | 250 (47.3%) |
| IFG (n = 498) | 61 (53–67) | 366 (73.5%) | 6 (1.2%) | 5 (1.0%) | 183 (36.7%) | 4 (0.8%) | 44 (8.8%) | 287 (57.6%) | ||
| p value | <0.001 | 0.039 | 0.919 | 0.747 | 0.409 | 0.718 | 0.611 | 0.001 | ||
| After PSM | NG (n = 431) | 60 (53–66) | 318 (73.8%) | 4 (0.9%) | 2 (0.5%) | 145 (33.6%) | 3 (0.7%) | 40 (9.3%) | 194 (45.0%) | |
| IFG (n = 431) | 60 (53–65) | 305 (70.8%) | 5 (1.2%) | 5 (1.2%) | 153 (35.5%) | 4 (0.9%) | 37 (8.6%) | 233 (54.1%) | ||
| p value | 0.709 | 0.323 | 1 | 0.451 | 0.567 | 1 | 0.720 | 0.008 | ||
| 5.3 mmol/L | Before PSM | NG (n = 595) | 58 (51–65) | 406 (68.2%) | 7 (1.2%) | 5 (0.8%) | 204 (34.3%) | 3 (0.5%) | 49 (8.2%) | 290 (48.7%) |
| IFG (n = 431) | 61 (53–67) | 317 (73.5%) | 5 (1.2%) | 4 (0.9%) | 160 (37.1%) | 4 (0.9%) | 37 (8.6%) | 247 (57.3%) | ||
| p value | <0.001 | 0.065 | 0.981 | 1 | 0.348 | 0.462 | 0.842 | 0.007 | ||
| After PSM | NG (n = 414) | 60 ± 9 | 285 (68.8%) | 3 (0.7%) | 2 (0.5%) | 138 (33.3%) | 3 (0.7%) | 38 (9.2%) | 160 (38.6%) | |
| IFG (n = 414) | 60 ± 9 | 303 (73.2%) | 5 (1.2%) | 4 (1.0%) | 153 (37.0%) | 4 (1.0%) | 35 (8.5%) | 231 (55.8%) | ||
| p value | 0.981 | 0.168 | 0.725 | 0.686 | 0.275 | 1 | 0.713 | < 0.001 | ||
| 5.4 mmol/L | Before PSM | NG (n = 640) | 58 (52–65) | 439 (68.6%) | 8 (1.3%) | 5 (0.8%) | 215 (33.6%) | 3 (0.5%) | 53 (8.3%) | 316 (49.4%) |
| IFG (n = 386) | 61 (53–67) | 284 (73.6%) | 4 (1.0%) | 4 (1.0%) | 149 (38.6%) | 4 (1.0%) | 33 (8.5%) | 221 (57.3%) | ||
| p value | <0.001 | 0.090 | 1 | 0.735 | 0.104 | 0.436 | 0.881 | 0.014 | ||
| After PSM | NG (n = 386) | 60 (53–67) | 282 (73.1%) | 4 (1.0%) | 2 (0.5%) | 144 (37.3%) | 3 (0.8%) | 32 (8.3%) | 117 (30.3%) | |
| IFG (n = 386) | 61 (53–67) | 284 (73.6%) | 4 (1.0%) | 4 (1.0%) | 149 (38.6%) | 4 (1.0%) | 33 (8.5%) | 221 (57.3%) | ||
| p value | 0.204 | 0.871 | 1 | 0.686 | 0.711 | 1 | 0.897 | < 0.001 | ||
| 5.5 mmol/L | Before PSM | NG (n = 688) | 59 (52–65) | 467 (67.9%) | 8 (1.2%) | 5 (0.7%) | 236 (34.3%) | 3 (0.4%) | 53 (7.7%) | 341 (49.6%) |
| IFG (n = 338) | 61 (54–68) | 256 (75.7%) | 4 (1.2%) | 4 (1.2%) | 128 (37.9%) | 4 (1.2%) | 33 (9.8%) | 196 (58.0%) | ||
| p value | <0.001 | 0.009 | 1 | 0.487 | 0.262 | 0.227 | 0.263 | 0.011 | ||
| After PSM | NG (n = 336) | 61 (53–67) | 264 (78.6%) | 4 (1.2%) | 2 (0.6%) | 105 (31.3%) | 3 (0.9%) | 33 (9.8%) | 87 (25.9%) | |
| IFG (n = 336) | 61 (54–68) | 254 (75.6%) | 4 (1.2%) | 4 (1.2%) | 127 (37.8%) | 4 (1.2%) | 32 (9.5%) | 194 (57.7%) | ||
| p value | 0.660 | 0.359 | 1 | 0.686 | 0.074 | 1 | 0.896 | < 0.001 | ||
| 5.6 mmol/L | Before PSM | NG (n = 735) | 59 (52–65) | 499 (67.9%) | 8 (1.1%) | 6 (0.8%) | 255 (34.7%) | 3 (0.4%) | 56 (7.6%) | 362 (49.3%) |
| IFG (n = 291) | 61 (54–68) | 224 (77.0%) | 4 (1.4%) | 3 (1.0%) | 109 (37.5%) | 4 (1.4%) | 30 (10.3%) | 175 (60.1%) | ||
| p value | < 0.001 | 0.004 | 0.749 | 0.719 | 0.404 | 0.105 | 0.161 | 0.002 | ||
| After PSM | NG (n = 291) | 61 (53–67) | 234 (80.4%) | 4 (1.4%) | 2 (0.7%) | 100 (34.4%) | 2 (0.7%) | 27 (9.3%) | 59 (20.3%) | |
| IFG (n = 291) | 61 (54–68) | 224 (77.0%) | 4 (1.4%) | 3 (1.0%) | 109 (37.5%) | 4 (1.4%) | 30 (10.3%) | 175 (60.1%) | ||
| p value | 0.531 | 0.311 | 1 | 1 | 0.437 | 0.686 | 0.781 | < 0.001 | ||
| 6.1 mmol/L | Before PSM | NG (n = 894) | 59 (52–65) | 620 (69.4%) | 9 (1.0%) | 7 (0.8%) | 313 (35.0%) | 7 (0.8%) | 71 (7.9%) | 456 (51.0%) |
| IFG (n = 132) | 62 (55–68) | 103 (78.0%) | 3 (2.3%) | 2 (1.5%) | 51 (38.6%) | 0 (0.0%) | 15 (11.4%) | 81 (61.4%) | ||
| p value | 0.002 | 0.041 | 0.193 | 0.326 | 0.416 | 0.604 | 0.185 | 0.026 | ||
| After PSM | NG (n = 130) | 61 ± 9 | 103 (79.2%) | 2 (1.5%) | 0 (0%) | 51 (39.2%) | 1 (0.8%) | 9 (6.9%) | 20 (15.4%) | |
| IFG (n = 130) | 61 ± 9 | 101 (77.7%) | 3 (2.3%) | 2 (1.5%) | 51 (39.2%) | 0 (0.0%) | 14 (10.8%) | 80 (61.5%) | ||
| p value | 0.861 | 0.763 | 1 | 0.498 | 1 | 1 | 0.275 | < 0.001 | ||
CHD: coronary heart disease; IFG: impaired fasting glucose; NG: normal glucose; PSM: propensity score match.